Posted September 29, 2012
Cancer research
By Bloomberg
Study: GSK melanoma combination slows cancer progress
Post a comment
Print this storyE-mail story
Share
Cancer research
Research Triangle Park, N.C. —
Patients taking Glaxo's dabrafenib and trametinib together delayed tumors from progressing for 9.4 months, compared with 5.8 months for patients taking dabrafenib alone, according to the study of 162 patients. The trial was part of the second of three phases of human testing usually required by regulators....Copyright 2013 Bloomberg. All rights reserved.
Please log in to view WRALTechWire Insider content
To access this premium content and other benefits, become a WRAL TechWire Insider. Daily, monthly, and annual memberships available.
Please Log In to add a comment.
